XCT790 is primarily used in research settings as a selective estrogen-related receptor alpha (ERRα) inverse agonist. It is utilized to study the role of ERRα in various biological processes, including metabolism, energy homeostasis, and cancer. Researchers employ XCT790 to investigate its potential in disrupting ERRα signaling pathways, which are implicated in the progression of certain cancers, such as breast and prostate cancer. Additionally, it serves as a tool to explore the metabolic functions of ERRα, particularly in relation to mitochondrial activity and cellular energy regulation. Its application in these studies helps in understanding the therapeutic potential of targeting ERRα in diseases where its activity is dysregulated.